Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (PH II-R) and Chemoradiation (PH III) as Adjuvant Treatment For Patients With Resected Head of Pancreas Adenocarcinoma

Next Previous
Search
Trial Profile

A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (PH II-R) and Chemoradiation (PH III) as Adjuvant Treatment For Patients With Resected Head of Pancreas Adenocarcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 24 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Erlotinib (Primary) ; Antineoplastics; Capecitabine; Fluorouracil; Gemcitabine
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 18 Mar 2025 Planned End Date changed from 13 Feb 2025 to 13 Feb 2026.
    • 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 29 Feb 2024 Planned End Date changed from 25 Jan 2025 to 13 Feb 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top